Navigation Links
VCU Massey Cancer Center sees potential in novel leukemia treatment
Date:5/22/2012

Richmond, Va. (May 22, 2012) Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much more effectively when combined than when the drugs are administered individually.

Recently published in the journal Blood, the results of a study led by Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey Cancer Center, and Mohamed Rahmani, Ph.D., associate professor in the Department of Internal Medicine at VCU School of Medicine, showed that the combination of obatoclax and sorafenib synergized to induce a form of cell suicide known as apoptosis and reduced the growth and survival of several types of AML cells while exerting only limited toxicity toward normal, healthy tissues. The results were first obtained in test-tube experiments and were then confirmed by similar findings and extended survival in animal models of AML.

"Prior research suggested that these two drugs may enhance each other's activity as they inhibit complementary survival pathways in leukemia cells," says Grant. "The results of our study are promising. We're looking forward to translating these findings into clinical trials, and we are hopeful we can bring a new, potentially more effective treatment to patients suffering from AML."

Sorafenib is currently approved by the Food and Drug Administration to treat kidney and liver cancers, but recently has been shown to kill a diverse array of malignant cells, including AML cells, particularly those with a specific mutation in a protein known as FLT3. Obatoclax is currently being investigated in clinical trials for various blood cancers.

In AML cells, Grant's team found the combination therapy caused profound cell death and mitochondrial injury, as well as prolonged survival in animal models. Both drugs inhibit the protein Mcl-1, but do so through different mechanisms. Mcl-1 is a protein that has been shown to prevent apoptosis in various cancer cells, and very recently has been shown to play a critical role in the survival of AML cells.

The combination of the two drugs nearly abolished Mcl-1 expression in AML cells, and in doing so unleashed Bax and Bak proteins. Bax and Bak are usually held in check by Mcl-1, and both help initiate apoptosis in cancer cells. Increased levels of Bim were also observed in treated cells. Bim is another pro-apoptotic protein that is often referred to as a "death trigger." Increased levels or activation of all three of these proteins contributed to the pronounced killing of AML cells.

Grant's team also observed protective mechanisms at play in the AML cells. The combination therapy induced autophagy, a process that diverts energy from less critical cellular constituents to enhance survival. Using chloroquine, a drug that suppresses immune responses and is typically used to treat malaria, the researchers were able to inhibit autophagy and increase AML cell death even further.

"When cancer cells are placed under stress, they seek any possible way to remain alive," says Grant. "The combination of these drugs served to block molecular 'escape routes,' leaving the cells no option other than suicide. Thus, it is theoretically possible that a third agent such as chloroquine may enhance the effectiveness of this regimen even further by reducing the cell's ability to induce autophagy."

Moving forward, Grant's team, led by Prithviraj Bose, M.D., assistant professor of internal medicine and hematologist-oncologist at Massey, is proposing a Phase I clinical trial testing this therapy in AML patients. The researchers are working with the involved drug companies, the National Cancer Institute and multiple potential collaborators to initiate the study.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. In the lab and clinic, VCU Massey develops a new therapy for blood cancers
2. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
3. VCU Massey first to combine targeted agents to kill multiple myeloma cells
4. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
5. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
6. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
7. VCU Massey research finds new link between inflammation and cancer
8. Scientists unravel role of fusion gene in prostate cancer
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. Colonoscopy May Detect Curable Cancer in Elderly: Study
11. U.S. Advisers Say No to Routine PSA Tests for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Cosmetic Town, ... plastic surgery procedures in order to make it easier for their readers to get ... the body they impact as well as the techniques used on those particular areas. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... ... 19, 2017 , ... In 2009, Carol Bryan endured immense ... severe facial disfiguration. After four frightening years of isolation and emotional and physical ... who removed the substances in a partial facial transplant through eight surgeries. ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Sam ... planning assistance to commercial and residential clients in the California Bay Area, is launching ... heart health in the region. , Heart disease is the primary killer of adult ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
(Date:1/19/2017)... -- South Korea Insulin Delivery Market ... "South Korea Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
(Date:1/18/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Breast Imaging Technologies Market by ... the global breast imaging technologies market size was valued at ... million by 2022, growing at a CAGR of 8.4% from ... Europe together accounted for over three-fourths ...
Breaking Medicine Technology: